The Centers for Medicare and Medicaid Services has issued its final payment decision for Exact Sciences’ FDA-approved noninvasive stool DNA colorectal cancer screening test Cologuard.
CMS will reimburse providers $502 per test. The payment decision follows a joint FDA and CMS review pilot program. Cologuard became the first technology to gain approval through this process.
“CMS’ final payment decision represents a major milestone by providing 50 million Medicare patients access to this noninvasive colorectal cancer screening option,” said Kevin Conroy, president, CEO and chairman of Exact Sciences.